Medicenna Presents Clinical Data on Initial Experience from Ongoing Phase 2b Study of MDNA55
They did not say how the patients did, but they did report that they were able to deliver the drug to the correct place in a higher percentage of the time than in previous trials. That was the big problem with previous trials involving convection enhanced delivery. In the first such trial, the PRECISE trial, it was found that most or all of the patients did not get the drug to the correct place - which didn't give the drug a chance to work - so the trial failed. More recently the Tocagen trials have used CED and have vastly improved the ability to get the drug where it needs to go. Hopefully this is another step toward getting the drug to the correct place 100% of the time.
(Disclaimer: Medicenna is a sponsor of the Musella Foundation)
Posted on: 10/10/2017
Click HERE to return to brain tumor news headlines